TRVI Stock Forecast & Price Target

Trevi Therapeutics Inc. is advancing its investigational therapy Haduvio, targeting chronic cough associated with idiopathic pulmonary fibrosis and prurigo nodularis, which indicates a focus on addressing significant unmet medical needs. The company's reliance on clinical data and development progress is a critical factor, as successful outcomes can lead to unlocking substantial market potential and enhancing revenue prospects. Additionally, the need for effective capital raising underscores the importance of maintaining operational flexibility, enabling Trevi to implement its commercialization strategy and support ongoing development efforts.

Trevi Therapeutics faces significant risk due to the potential failure of its clinical trials for Haduvio, as disappointing outcomes or unforeseen safety issues could lead to asset impairment or diminished value. The company is operating in highly competitive therapeutic areas, which could further jeopardize its ability to successfully market Haduvio and achieve a return on investment. Additionally, Trevi is expected to require further capital to sustain operations before reaching profitability, contributing to financial uncertainty and potential volatility in its stock price.